A new global study shows that an immunotherapy drug can delay the onset of type 1 diabetes for two years in high risk kids and adults.
The study ran in 28 research sites.
Trial results are great news for the relatives of the millions of people with diabetes, who are fifteen times more likely to get the disease.
Courtney Hunter explains in Healthy Living.
Dr. Buckner says trials are being planned to extend the benefits of Teplizumab, perhaps even preventing diabetes altogether.
© 2023 - 910 Media Group